MedTrace Logo

Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC

NCT05969184 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2023-08-01

No results posted yet for this study

Summary

This study is to find out that if HER-2 positive and HR positive patients could benefit from trastuzumab and pertuzumab combined with palbociclib and endocrine therapy.

Conditions

  • Breast Neoplasm Female

Interventions

DRUG

CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou)

CDK4/6 inhibitor (Qilu) have got the cFDA approval and Trastuzumab (Hanquyou) have few data on combination use, this two drugs need clinical treatment data

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    lead OTHER

Principal Investigators

  • Yaxin Liu, Dr · Peking University Cancer Hospital and Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-25
Primary Completion
2023-12-25
Completion
2024-12-25

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05969184 on ClinicalTrials.gov